166 related articles for article (PubMed ID: 35707213)
21. Sensitivity Analysis for Restricted Mean Survival Time When Survival Curves Have Divergent Tails.
Ueno K; Morita S
Ther Innov Regul Sci; 2023 May; 57(3):467-471. PubMed ID: 36596962
[TBL] [Abstract][Full Text] [Related]
22. Restricted mean survival time as a summary measure of time-to-event outcome.
Hasegawa T; Misawa S; Nakagawa S; Tanaka S; Tanase T; Ugai H; Wakana A; Yodo Y; Tsuchiya S; Suganami H;
Pharm Stat; 2020 Jul; 19(4):436-453. PubMed ID: 32072769
[TBL] [Abstract][Full Text] [Related]
23. [Application of restricted mean survival time in clinical follow-up study].
Yang ZJ; Lyu JJ; Hou YW; Chen Z
Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):247-250. PubMed ID: 30744281
[TBL] [Abstract][Full Text] [Related]
24. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
Tang Y
Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
[TBL] [Abstract][Full Text] [Related]
25. Group sequential monitoring based on the maximum of weighted log-rank statistics with the Fleming-Harrington class of weights in oncology clinical trials.
Prior TJ
Stat Methods Med Res; 2020 Dec; 29(12):3525-3532. PubMed ID: 32522077
[TBL] [Abstract][Full Text] [Related]
26. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.
Pak K; Uno H; Kim DH; Tian L; Kane RC; Takeuchi M; Fu H; Claggett B; Wei LJ
JAMA Oncol; 2017 Dec; 3(12):1692-1696. PubMed ID: 28975263
[TBL] [Abstract][Full Text] [Related]
27. Visualizing hypothesis tests in survival analysis under anticipated delayed effects.
Jiménez JL; Barrott I; Gasperoni F; Magirr D
Pharm Stat; 2024 May; ():. PubMed ID: 38708672
[TBL] [Abstract][Full Text] [Related]
28. A novel design for randomized immuno-oncology clinical trials with potentially delayed treatment effects.
He P; Su Z
Contemp Clin Trials Commun; 2015 Oct; 1():28-31. PubMed ID: 29736436
[TBL] [Abstract][Full Text] [Related]
29. A win ratio approach for comparing crossing survival curves in clinical trials.
Zheng S; Wang D; Qiu J; Chen T; Gamalo M
J Biopharm Stat; 2023 Jul; 33(4):488-501. PubMed ID: 36749067
[TBL] [Abstract][Full Text] [Related]
30. Comparison of methods to testing for differential treatment effect under non-proportional hazards data.
Pardo MDC; Cobo B
Math Biosci Eng; 2023 Sep; 20(10):17646-17660. PubMed ID: 38052530
[TBL] [Abstract][Full Text] [Related]
31. On assessing survival benefit of immunotherapy using long-term restricted mean survival time.
Horiguchi M; Tian L; Uno H
Stat Med; 2023 Apr; 42(8):1139-1155. PubMed ID: 36653933
[TBL] [Abstract][Full Text] [Related]
32. Sample size and power for the weighted log-rank test and Kaplan-Meier based tests with allowance for nonproportional hazards.
Yung G; Liu Y
Biometrics; 2020 Sep; 76(3):939-950. PubMed ID: 31797363
[TBL] [Abstract][Full Text] [Related]
33. Power and sample size calculation for log-rank test with a time lag in treatment effect.
Zhang D; Quan H
Stat Med; 2009 Feb; 28(5):864-79. PubMed ID: 19152230
[TBL] [Abstract][Full Text] [Related]
34. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
Royston P; Parmar MK
Trials; 2014 Aug; 15():314. PubMed ID: 25098243
[TBL] [Abstract][Full Text] [Related]
35. A comparative study to alternatives to the log-rank test.
Dormuth I; Liu T; Xu J; Pauly M; Ditzhaus M
Contemp Clin Trials; 2023 May; 128():107165. PubMed ID: 36972865
[TBL] [Abstract][Full Text] [Related]
36. Omnibus test for restricted mean survival time based on influence function.
Gu J; Fan Y; Yin G
Stat Methods Med Res; 2023 Jun; 32(6):1082-1099. PubMed ID: 37015346
[TBL] [Abstract][Full Text] [Related]
37. Methods for non-proportional hazards in clinical trials: A systematic review.
Bardo M; Huber C; Benda N; Brugger J; Fellinger T; Galaune V; Heinz J; Heinzl H; Hooker AC; Klinglmüller F; König F; Mathes T; Mittlböck M; Posch M; Ristl R; Friede T
Stat Methods Med Res; 2024 Jun; 33(6):1069-1092. PubMed ID: 38592333
[TBL] [Abstract][Full Text] [Related]
38. Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer.
Liang F; Zhang S; Wang Q; Li W
Ann Oncol; 2018 May; 29(5):1320-1324. PubMed ID: 29788167
[TBL] [Abstract][Full Text] [Related]
39. Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard.
Wang Z; Zhang Q; Xue A; Whitmore J
Pharm Stat; 2024; 23(3):325-338. PubMed ID: 38152873
[TBL] [Abstract][Full Text] [Related]
40. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
Jachno K; Heritier S; Wolfe R
BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
